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The cost data for MM ASCT was obtained from published
data of direct hospital costs obtained from Nationwide
Inpatient Sample and were converted to Medicare cost-to-
charge ratio. Chemotherapy cost consisted of average
wholesale prices AWP (2008), costs of medical oncology
visits, and cost of managing adverse events. TreeAge Pro
2012 software was used to perform a static decision analysis.
The outcomes were expressed in the units of health utility
values obtained from phase III HOVON trial which measured
quality of life (QoL) using EORTC QLQ-C30 & EuroQoL-5D
scales. Using a Consumer Price Index (CPI), the costs were
converted into 2012 US$. The expected cost of providing
treatment to newly diagnosed MM patients for a period of 5
yrs when they undergo eASCT after induction with IMiD was
$211,869 ($52,454 less than the dASCT) and had an expected
beneﬁt of 2.06 QALYs following treatment (0.19 QALYs more
than dASCT) implying that eASCT is preferred over (domi-
nates) dASCT. Tornado diagram and one-way sensitivity
analysis results indicated that eASCT showed dominance
even if the probability of OSwas lowered to 52.1% (from BC of
65%), or the probability of ORR was lowered to 75.8% (from
BC of 92%), or the probability of 1 year TRM was increased to
11.5% (from BC of 2%).
In absence of a survival beneﬁt, the cost savings of early
ASCT as measured by ICER would favor this approach, and it
would help clinicians, patients, policy makers and third party
payers in decision making. Future prospective studies in MM
ASCT should incorporate economic and QOL components in
the analysis and also focus on the added cost of post-ASCT
maintenance therapies.
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treatment for eligible patients with AL, a disease in which
hematologic response is a key determinant of survival. With
the advent of novel agents the role of SCT for patients with AL
is being questioned, especially given safety concerns. Yet
with appropriate patient selection and the use of risk-
adapted SCT (RA-SCT), treatment-related mortality (TRM)
improved. (Br J Haem 2007;139:224; Bone Marrow Trans-
plantation 2011; 46:970) Beginning in 2002, we showed in 2
consecutive phase II trials that following RA-SCT patients can
safely receive consolidation with thalidomide and dexa-
methasone (TD) or bortezomib and D (BD), with the goal of
improving hematologic response thereby extending overall
survival (OS). (Br J Haem 2007;139:224; Amyloid
2010;17:80a) Consolidation was administered for patients
achieving less than a complete response (CR). We now
describe the outcomes of all patients with AL who under-
went RA-SCT at Memorial Sloan-Kettering Cancer Center
(MSKCC) since the year 2000.
Methods:Weperformeda retrospective study toassess theOS
of all patients who underwent SCT for a diagnosis of AL
conﬁrmed at MSKCC. Patients who had >2 major organs
involved, NYHA class III or greater CHF, critical arrhythmias or
cardiac syncopewere ineligible for SCT.OSwascalculated from
transplant to date of death or last follow up. Median survival
was estimated by Kaplan Meier methods. Log-rank test was
used to determine whether survival functions differed by
covariates of interest. Cumulative incidence functionwas used
to estimate the incidence of cause-speciﬁc mortality.
Results: A total of 151 patients underwent RA-SCT between
February 2000 and June 2011; three lost to follow-up are
excluded from this analysis. Of the remaining 148 patients
21%, 52% and 34% received RA-SCTat 100,140 and 200mg/m2
of melphalan respectively based on age, renal function and
cardiac involvement.(Blood 2002; 99: 4276) Five patients
died within 100 days of SCT (TRM 3.4%). At a median follow
up of 6.7 years, the median OS for all patients is 11.1 years
(95% CI, 7.32 - not reached-NR) (Figure 1), and for patients
who received MEL 100, 140 or 200 is 4.4 (95% CI, 2.7 e 6.3),
NR and 11 years (95% CI, 8.2 e NR) respectively (P  0.01).
Cumulative incidence of disease related mortality at 2 years
is 5.5%, and subsequently the rate of death from other
causes exceeds that due to AL.
Conclusions: RA-SCT for appropriately selected patients is
safe and is associated with excellent long-term survival.
Consolidation with novel agents may improve survival
followingRA-SCTand likelyaccounts for the similarOS seen in
patients who received MEL 140 and 200. In the era of novel
agents available for post-SCT consolidation, RA-SCT is an
effective and important initial treatment for patients with AL.
Figure 1. Survival from SCT.
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This prospective, multi-center study investigated the
utility of pre-conditioning test pharmacokinetics (PK) of
intravenous busulfan (IV Bu) to optimize dosing in 204
subjects with Hodgkin (n¼64) and B-cell non-Hodgkin
lymphoma (n¼140) at 32 centers in the US and Canada. PK
studies were conducted twice during the study: test PK on
Day -14 to -11 and conﬁrmatory PK on the ﬁrst day of
conditioning, Day -8. The test PK used a 2-hour infusion of
a single IV Bu dose (0.8mg/kg) in order to determine the area
under the concentration-time curve (AUC). The test PKTable 1
AUC Exposure and Clearance from a Test Dose of 0.8 mg/kg IV Bu by Different BM
BMI Category (kg/m2)
BMI (kg/m2)
(Mean  SD)
Clearance (mL/min/
kg) Median (range)
AUC from
<1,000 m
Under Weight (<18.5) 17.9  0.51 2.76 (2.50 - 2.99) 0
Normal (18.5 - 24.9) 22.9  1.63 2.85 (1.95 - 4.39) 10 (18.5
Over Weight (25.0 - 29.9) 27.6  1.48 2.92 (2.15 - 4.11) 23 (33.8
Obese (>30.0) 35.4  5.10 3.16 (2.43 - 4.20) 35 (44.3dosing was based on adjusted ideal body weight (AIBW) for
all patients except for the subjects whose actual BW was less
than or equal to the ideal BW, where actual BW was used.
AIBW was calculated by adding 25% of the difference
between ideal BW and actual BW to ideal BW. The condi-
tioning dose of daily IV Bu was then calculated to achieve
20,000 mM*min as a total AUC. The same individualized Bu
dose was administered over 3 hours once daily from Day -8
to Day -5. If needed, dose was further adjusted on Days -6
and -5 based on conﬁrmatory PK results. VP-16 (1.4 g/m2)
was administered on Day -4, followed by 2.5 g/m2/day of
cyclophosphamide on Days -3 and -2.
Test PK from 204 subjects showed that 6 subjects (2.9%)
had higher AUC than expected (>1,500 mM*min) and 68
subjects (33.3%) had lower AUC (<1,000 mM*min). Therefore,
total AUC would have fallen outside the target range in 74
subjects (36.3%) if PK-directed dose adjustment had not been
performed. The discrepancy between expected and observed
exposure was not predicted by subject height, actual body
weight, body mass index (BMI) or body surface area. For
example, although a greater proportion of patients with high
BMI were underexposed compared with those with normal
BMI, the difference was not signiﬁcant [Table 1]. In addition,
all patients who had AUC>1,500 mM*min had normal or high
BMI. Thus, it is not possible to prospectively identify the
subpopulation which has a risk of suboptimal Bu exposure
and would gain the most beneﬁt from PK-directed dose
optimization.Hence, PK-directeddoseoptimization shouldbe
considered for all subjects when tight regulation of Bu expo-
sure is critical, and should not be limited to subpopulations.
Out of 200 patients whose conﬁrmatory PK results were
evaluable, 190 subjects (95.0%) fell within the target range
(AUC: 20,000 mM*min  20%). Eight (4.0%) and two (1.0%)
patients required dose reductions and increases, respec-
tively, for the last two days of Bu dosing. Again, no predictive
factor was identiﬁed for these patients.
In conclusion, a pre-conditioning small dose of IV Bu
estimated individual PK parameters and predicted Day-8 PK
in 95% of the subjects. This relatively large PK study identi-
ﬁed no factor that could predict outliers linked to Bu
metabolism. Therefore, when Bu exposure has to be tightly
controlled, PK-directed dose optimization should be con-
ducted for all patients.42
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Test Dose of 0.8 mg/kg (n)
Total (n)M*min 1,000-1,500 mM*min >1,500 mM*min
4 (100 %) 0 4
%) 40 (74.0%) 4 (7.4%) 54
%) 42 (62.7%) 2 (3.0%) 67
%) 44 (55.7%) 0 79
